DEPO MEDROXYPROGESTERONE ACETATE (DMPA) USE IN OBESE AND MORBIDLY OBESE WOMEN

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 本研究的目的是确定醋酸甲孕酮(DMPA)在肥胖和病态肥胖女性中的促糖尿病和增脂作用。我们将通过比较使用DMPA前和使用后4.5个月的IVGTT、OGTT、DEXA扫描、血脂、瘦素、CRP和Adinponectin结果来实现这一点。这项初步研究将有助于了解这种避孕药对肥胖和混合性肥胖女性的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine the diabetogenic and lipogenic effects of Depo Medroxyprogesterone Acetate (DMPA) use in the obese and morbidly obese women. We will accomplish this by comparing IVGTT, OGTT, DEXA scan, Lipid panel, Leptin, CRP, and Adinponectin results before and after 4.5 months of DMPA use. This pilot study wil;l be instrumental in the understanding effects of this contraceptive agent in obese and mobidly obese women.